Aging-associated diseases

EQS-News: Cureus delivers a strong Q3 2022 and is superbly positioned for the future

Retrieved on: 
Tuesday, October 11, 2022
EPRA, CFO, KfW, Risk, Growth, ESG, Education, Architecture, Global, Aging-associated diseases, Research, Completion, European Public Real Estate Association, Sustainalytics, Certification, BayernLB, GRI, Health, CEO, Environment, Maintenance, Efficiency, Hospital, Construction, Bank, Real estate, Renewable energy, Entertainment, Cureus

We have also been able to secure an ample and secure financial buffer, which will allow us to drive our future growth.

Key Points: 
  • We have also been able to secure an ample and secure financial buffer, which will allow us to drive our future growth.
  • Since the beginning of 2022, Cureus has raised a total of around EUR250million from its financing partners.
  • Cureus continued to successfully expand its real estate portfolio in various regions of Germany in Q3 2022.
  • The constant review and optimisation of the Cureus system care home standard guarantees the construction of care homes that truly meet demand.

The Worldwide Somatostatin Analogs Industry is Expected to Reach $9.1 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 17, 2022
Health, Biotechnology, Certification, Use, Cushing's syndrome, Strategic management, R, Market share analysis, Decision-making, Incidence, Technology, USD, Value, Acquisition, Growth, Investment, Aging-associated diseases, COVID-19, Customer support, Business Growth Fund, CAGR, Retail, Fine chemical, Acromegaly

What are the inhibiting factors and impact of COVID-19 shaping the Global Somatostatin Analogs Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Somatostatin Analogs Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Somatostatin Analogs Market?
  • What is the market share of the leading vendors in the Global Somatostatin Analogs Market?
  • What modes and strategic moves are considered suitable for entering the Global Somatostatin Analogs Market?

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending

Retrieved on: 
Wednesday, August 4, 2021
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Psychiatry, Psychiatric diagnosis, Branches of biology, Cognitive disorders, Learning disabilities, Neuroscience, Dementia, Aging-associated diseases, Alzheimer's disease, Geriatric psychology

Dementia is not a normal part of aging, and there are numerous symptoms that can indicate cognitive and neurological impairments.

Key Points: 
  • Dementia is not a normal part of aging, and there are numerous symptoms that can indicate cognitive and neurological impairments.
  • Over 47 million people in the world currently live with Alzheimers disease or dementia, with over 6.2 million in the U.S. (two-thirds are women).
  • According to the Alzheimers Association, it is estimated that Alzheimers and dementia deaths increased more than 16% in 2021 due to COVID-19.
  • More information, including potential risk factors, that could affect Alzamends business and financial results are included in Alzamends filings with the U.S. Securities and Exchange Commission.

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Retrieved on: 
Monday, August 2, 2021
Musculoskeletal system, Organ systems, Anatomy, Osteopathies, Skeletal system, Aging-associated diseases, Endocrine diseases, Rheumatology, Osteoporosis, Bone density, Bone, Entera

BOSTON and JERUSALEM, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its poster presentation titled “A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass - An Interim Three-Month Analysis” has been selected by the Program Committee of the American Society for Bone and Mineral Research (ASBMR) for its Annual Meeting scheduled to take place on October 1-4, 2021 in San Diego, California. Dr. Arthur Santora, Entera’s Chief Medical Officer, will present the poster at both the plenary session on October 1 and the general session on October 2, as well as a special session on the Biology of the Aging Skeleton Symposium on September 30.

Key Points: 
  • Three and 6 month results, previously reported by Entera in June 2021 can be found here .
  • Osteoporosis, characterized by low bone mass and deterioration of bone tissue, can lead to decreased bone strength and increased risk of fracture.
  • The Companys most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Highlights From The Alzheimer's Association International Conference 2021

Retrieved on: 
Thursday, July 29, 2021
Psychiatry, Cognitive disorders, Psychiatric diagnosis, Branches of biology, Learning disabilities, Neuroscience, Alzheimer's Association, Dementia, Aging-associated diseases, AAIC, Alzheimer's disease

DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.
  • Other new data reported at AAIC 2021 included:
    Improving air quality may reduce dementia risk.
  • The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.
  • The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research.

Medimaps Announces Reimbursement by Center for Medicare and Medicaid Services (CMS) for Trabecular Bone Score for Osteoporosis Fracture Risk Assessment

Retrieved on: 
Thursday, July 29, 2021
Health, Technology, Managed care, Software, Radiology, Biotechnology, Musculoskeletal disorders, Musculoskeletal system, Organ systems, Osteopathies, Aging-associated diseases, Endocrine diseases, Rheumatology, Osteonecrosis, Osteoporosis, Bone density, Medication-related osteonecrosis of the jaw, Bone fracture

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.

Key Points: 
  • This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.
  • The reimbursement amount was released by CMS last week and will become effective and available January 1, 2022.
  • This is largely a result of the fact that 75% of high-risk patients are not being diagnosed timely4.
  • Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, Journal of Bone and Mineral Research.

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Protein O-GlcNAcase, Neurological disorders, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Dementia

Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Protein O-GlcNAcase, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Tau protein

LAUSANNE, Switzerland and SAN FRANSICO, July 28, 2021 /PRNewswire/ -- Asceneuron SA, a clinical-stage biotech company dedicated to targeting the root cause of neurodegenerative diseases, is pleased to announce that Chief Executive Officer, Dirk Beher has been invited to present at The Peter Davies Memorial Symposium: The Future of Tau Based Therapies during the prestigious Alzheimer's Association International Conference which takes place between the 26 – 30 July 2021 in Denver, USA and online. The talk will take place on Wednesday, 28 July at 08:00am MDT / 4:00pm CET.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.
  • The Peter Davies Memorial Symposium: The Future of Tau Based Therapies (preclinical, early phase, current studies, future)

Global Dementia Cases Forecasted To Triple By 2050

Retrieved on: 
Tuesday, July 27, 2021
Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Abnormal psychology, Branches of biology

DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.

Key Points: 
  • DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
  • Nichols and team found dementia would increase from an estimated 57.4 (50.4 to 65.1) million cases globally in 2019 to an estimated 152.8 (130.8 to 175.6) million cases in 2050.
  • They found an increase of 6.8 million dementia cases globally between 2019 and 2050 due specifically to expected changes in these risk factors.
  • The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019.

Global Dementia Cases Forecasted To Triple By 2050

Retrieved on: 
Tuesday, July 27, 2021
Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Abnormal psychology, Branches of biology

DENVER, July 27, 2021 /PRNewswire/ -- Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050. Meanwhile, anticipated trends in smoking, high body mass index and high blood sugar are predicted to increase prevalence by nearly the same number: 6.8 million cases. Both according to new global prevalence data reported at the Alzheimer's Association International Conference® (AAIC®) 2021 in Denver and virtually.

Key Points: 
  • DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
  • Nichols and team found dementia would increase from an estimated 57.4 (50.4 to 65.1) million cases globally in 2019 to an estimated 152.8 (130.8 to 175.6) million cases in 2050.
  • They found an increase of 6.8 million dementia cases globally between 2019 and 2050 due specifically to expected changes in these risk factors.
  • The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019.